Cargando…
Cytokines and microRNAs in SARS-CoV-2: What do we know?
The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233348/ https://www.ncbi.nlm.nih.gov/pubmed/35782361 http://dx.doi.org/10.1016/j.omtn.2022.06.017 |
_version_ | 1784735743573229568 |
---|---|
author | Rarani, Fahimeh Zamani Rashidi, Bahman Jafari Najaf Abadi, Mohammad Hassan Hamblin, Michael R. Reza Hashemian, Seyed Mohammad Mirzaei, Hamed |
author_facet | Rarani, Fahimeh Zamani Rashidi, Bahman Jafari Najaf Abadi, Mohammad Hassan Hamblin, Michael R. Reza Hashemian, Seyed Mohammad Mirzaei, Hamed |
author_sort | Rarani, Fahimeh Zamani |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19. |
format | Online Article Text |
id | pubmed-9233348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-92333482022-06-27 Cytokines and microRNAs in SARS-CoV-2: What do we know? Rarani, Fahimeh Zamani Rashidi, Bahman Jafari Najaf Abadi, Mohammad Hassan Hamblin, Michael R. Reza Hashemian, Seyed Mohammad Mirzaei, Hamed Mol Ther Nucleic Acids Review The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19. American Society of Gene & Cell Therapy 2022-06-25 /pmc/articles/PMC9233348/ /pubmed/35782361 http://dx.doi.org/10.1016/j.omtn.2022.06.017 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rarani, Fahimeh Zamani Rashidi, Bahman Jafari Najaf Abadi, Mohammad Hassan Hamblin, Michael R. Reza Hashemian, Seyed Mohammad Mirzaei, Hamed Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title | Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title_full | Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title_fullStr | Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title_full_unstemmed | Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title_short | Cytokines and microRNAs in SARS-CoV-2: What do we know? |
title_sort | cytokines and micrornas in sars-cov-2: what do we know? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233348/ https://www.ncbi.nlm.nih.gov/pubmed/35782361 http://dx.doi.org/10.1016/j.omtn.2022.06.017 |
work_keys_str_mv | AT raranifahimehzamani cytokinesandmicrornasinsarscov2whatdoweknow AT rashidibahman cytokinesandmicrornasinsarscov2whatdoweknow AT jafarinajafabadimohammadhassan cytokinesandmicrornasinsarscov2whatdoweknow AT hamblinmichaelr cytokinesandmicrornasinsarscov2whatdoweknow AT rezahashemianseyedmohammad cytokinesandmicrornasinsarscov2whatdoweknow AT mirzaeihamed cytokinesandmicrornasinsarscov2whatdoweknow |